Cadila: Zydus receives final approval for acyclovir ointment

Pharma major Cadila Healthcare Limited informed the exchanges that Zydus has received the final approval from the US Food and Drug Administration (USFDA) for acyclovir ointment.

The ointment is a generic version of GSK's Zovirax (acyclovir) Cream, 5%. Acyclovir is a synthetic nucleoside analogue active against herpes viruses. It is used to treat the outbreak of genital herpes infection. It is also used to treat non-life threatening herpes infections of the skin and around the mouth in people with weak immunity. The drug will be manufactured at the group’s topical manufacturing facility at Ahmedabad.

Earlier last week, the company received final approval from USFDA to market Valsartan and Hydrochlorothiazide Tablets USP used to treat high blood pressure.

With this, the group has 257 approvals as against 350 ANDAs filed so far.

Zydus Cadila is an innovative, pharma company that develops, manufactures and markets a range of healthcare therapies, globally.

In Tuesday's afternoon session, the stock of Cadila Healthcare was trading at Rs. 339.35 per share, up by 0.03 per cent after hitting an intraday high of Rs. 344.00 per share in the morning session.